Ixekizumab is novel drug approved by the FDA for treatment of psoriasis, MOA of this drug is :
Correct Answer: IL-17A antagonist
Description: Ixekizumab, approved for treatment of plaque psoriasis. It is a humanized IL-17A antagonist that works when IgG4 monoclonal antibodies selectively bind with IL-17A cytokines and inhibit their interaction with the IL-17 receptor. Secukinumab, similar to Ixekizumab, this injectable is an IgG1 monoclonal antibody that selectively binds to the IL-17A cytokine and inhibits its interaction with the IL-17 receptor. It is approved for the treatment of plaque psoriasis and psoriatic ahritis. Ustekinumab : Anti IL-12/23 Apremilast: PDE-4 inhibitor
Category:
Dental
Get More
Subject Mock Tests
Practice with over 200,000 questions from various medical subjects and improve your knowledge.
Attempt a mock test nowMock Exam
Take an exam with 100 random questions selected from all subjects to test your knowledge.
Coming SoonGet More
Subject Mock Tests
Try practicing mock tests with over 200,000 questions from various medical subjects.
Attempt a mock test now